Pharmacoeconomic challenges in disease management of hypertension

Journal of Hypertension, Supplement

Volumn 19, Issue 3, 2001, Pages

  Ambrosioni, E ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antihypertensive treatment; Combination therapy; Compliance; Cost effectiveness; Hypertension; Pharmacoeconomics

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DRUG COST; DRUG TOLERABILITY; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; HYPERTENSION; LONG TERM CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; BLOOD PRESSURE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DEMOCRATIC REPUBLIC CONGO; DRUG COMBINATION; ECONOMICS; EUROPE; PHARMACOECONOMICS; PHYSIOLOGY; QUALITY OF LIFE; TREATMENT OUTCOME; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DEMOCRATIC REPUBLIC OF THE CONGO; DRUG THERAPY, COMBINATION; ECONOMICS, PHARMACEUTICAL; EUROPE; HUMANS; HYPERTENSION; QUALITY OF LIFE; TREATMENT OUTCOME; UNITED STATES;

EID: 0035161460     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Cost-effectiveness calculations from trials
2. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
3. Blood pressure as a cardiovascular risk factor. Prevention and treatment
4. Pharmacoeconomic considerations in the management of hypertension
5. Health and disease management: What is it and where is it going? What is the role of health and disease management in hypertension?
6. The costs of treating hypertension. What are the long-term realities of cost containment and pharmacoeconomics?
7. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991
8. Rationale for the use of a fixed combination in the treatment of hypertension
9. Cost of hypertension treatment and the price of health
10. Use of antihypertensive drugs in Spain, 1985-1995
11. The economics of hypertension control: Some basic issues
12. Cost-effectiveness of combination therapy. Based on a presentation by David Hilleman, PharmaD
13. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension
14. Cost-benefit of treating hypertension
15. Pressure to treat and pressure to cost: A review of cost-effectiveness analysis
16. Assessing the economic value of antihypertensive medicines
17. What a physician needs to know about cost-effectiveness
18. Pharmacoeconomics of hypertension control: Basic principles of economic evaluation
19. Allocation of resources to manage hypertension
20. A computer model for cost-effectiveness analysis of cardiovascular disease prevention
21. The impact of age on the cost-effectiveness of hypertension treatment: An analysis of randomized drug trials
22. The cost effectiveness of hypertension treatment in Sweden
23. The cost-effectiveness of hypertension treatment in Sweden: An analysis of the criteria for intervention and the choice of drug treatment
24. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context
25. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease
26. The benefits of treating mild to moderate hypertension. A quantitative estimation of the life expectancy gains from pharmacological reduction of blood pressure
27. Treating mild to moderate hypertension: Cost-effectiveness and policy implications
28. The cost-effectiveness of treating mild-to-moderate hypertension: A reappraisal
29. A review of cost-effectiveness analyses of hypertension treatment
30. Combination therapy for systemic hypertension
31. Blood pressure screening, management and control in England: Results from the health survey for England 1994
32. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy
33. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
34. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
35. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials
36. Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to beta-blockade
37. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
38. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
39. Quality of life in treatment of hypertension. A meta-analysis of clinical trials
40. The effects of antihypertensive therapy on the quality of life
41. Noncompliance with antihypertensive therapy
42. Noncompliance with medication regimens and subsequent hospitalizations: A literature analysis and cost of hospitalization estimate
43. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens
44. Discontinuation and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population
45. The costs of interrupting antihypertensive drug therapy in a Medicaid population
46. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension
47. Patterns of hypertension management in Italy: Results of a pharmacoepidemiological survey on antihypertensive therapy
48. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data
49. Variations in hypertension control in indigent rural primary care clinics in North Carolina
50. Blood pressure control in the hypertensive population
51. Hypertension awareness, treatment and control in the community: Is the 'rule of halves' still valid?
52. Existing treatment strategies: Does noncompliance make a difference?
53. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: Results from a population-based study in the elderly
54. Variations in compliance among hypertensive patients by drug class: Implications for health care costs
55. The importance of drug combinations for effective control of hypertension
56. Strategies for improving blood pressure control
57. The heterogeneity of hypertension: Why doesn't every patient respond to every antihypertensive drug?
58. Essential hypertension. Part I: Definition and etiology
59. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension
60. Main objectives and new aspects of combination treatment of hypertension
61. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
62. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients
63. Very-low-dose perindopril 2 mg/indapamide 0.625 mg combination gives higher response and normalization rates than losartan 50 mg in the treatment of essential hypertension
64. Effect of low doses of perindopril and indapamide alone or in combination (Preterax) in renovascular hypertensive rats
65. The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats
66. Changes in antihypertensive therapy - The role of adverse effects and compliance
67. Remembering the lessons of basic pharmacology
68. Combination antihypertensive therapy: Does it have a role in rational therapy?
69. Cost-effectiveness of felodipine-metoprolol and enalapril in the treatment of hypertension